Successful Type C Meeting with US FDA Regarding Ph 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma Announced
“We were very pleased that we made meaningful progress with the FDA on the potential of using immune activation biomarker data as a surrogate endpoint of clinical efficacy and on the proposed design of a confirmatory study design required to be initiated prior to received Accelerated Approval,” said Paul Romness, Chairman & CEO of OS Therapies. “Dr. Anderson’s meaningful contribution helped shape the conversation about the significant unmet medical need and inform the agency about the critical value of Comparative Oncology in potentially helping speed therapies to market in osteosarcoma. We expect not only to have biomarker data from our human clinical study to share with FDA, but also to have additional biomarker data from our canine program in frontline osteosarcoma which is the disease setting that FDA suggested may be suitable to conduct a confirmatory randomized study as part of an agreement with the agency regarding Accelerated Approval.”
Share:
More News
“Pancreatic cancer has historically been one of the most difficult-to-treat cancers and people whose tumors harbor a KRAS G12C mutation face limited options once their disease progresses,” said Jacob Van Naarden, executive vice president, and president of Lilly Oncology. “This Breakthrough Therapy designation reflects the early potential we’re seeing with
“This financing reflects the confidence our investors and strategic partners have in the progress we have made to date and the opportunities that lie ahead,” said Dr. Jack Hoppin, Chief Executive Officer of Ratio Therapeutics. “As we march the ATLAS trial forward and prepare for our 5th IND filing, these
“We are excited to initiate monotherapy expansion evaluating IDE892 in MTAP-deleted PDAC and NSCLC. We designed IDE892 to be a potential best-in-class PRMT5 inhibitor, including approximately 1,400-fold selective MTA-PRMT5 cooperative binding versus SAM-PRMT5 cooperative binding, lack of brain penetrance, and favorable drug-like properties intended to maximize its therapeutic window as
“The data presented at ASCO provided important insight into the potential clinical path for CRB-701 in 2L oropharyngeal cancer, a distinct tumor-type that is on the rise due to HPV infections,” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. “Unfortunately, current treatment options have shown limited efficacy underscoring the